TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30511200
Drug: TAS-114 combined
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-114 combined with S-1, administered orally under fasting conditions at doses ranging from 5-240 mg/m
Study: 30511337
Drug: Response to
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response to percutaneous coronary intervention, platelets, sex hormones, and myocardial damage at baseline
Study: 30513489
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for HD participants, 16 weekly sessions.
Study: 30517727
Drug: Hazelnuts (∼57
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hazelnuts (∼57 g/d) for 16 weeks
Study: 30518443
Drug: Thrombolysis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis treatment group (110 patients)
Study: 30518443
Drug: Non-thrombolysis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-thrombolysis treatment group (94 patients)
Study: 30518502
Drug: Axicabtagene ciloleucel
Normalized name: Axicabtagene ciloleucel
DrugBank: Axicabtagene ciloleucel (DB13915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axicabtagene ciloleucel (target dose of 2 × 10^5 cells) administered on day 0
Study: 30519877
Drug: Life support-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life support-based comprehensive treatment regimen including mechanical life support, immunological modulation with glucocorticoids and immunoglobulin, and antiviral reagents (neuraminidase inhibitor)
Study: 30520001
Drug: Bupropion XL
Normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupropion XL 150 mg once daily for 5 days, then 300 mg once daily from days 6 to 14
Study: 30522700
Drug: Pembrolizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (10 mg/kg every 2 weeks for ≤24 months)
Study: 30522992
Drug: Usual psychopharmacological
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual psychopharmacological therapy plus the Social-Local-Mobile app
Study: 30522992
Drug: Usual psychopharmacological
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual psychopharmacological therapy
Study: 30523039
Drug: Various modifiable
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various modifiable risk factors (e.g., diet, supplement use, physical activity)
Study: 30523039
Drug: Biomarkers (e.g.,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarkers (e.g., metabolomic, transcriptomic, metagenomic, genetic, epigenetic, proteomic markers)
Study: 30523489
Drug: Blood drug
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood drug concentrations in plasma
Study: 30524509
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (varenicline + nicotine patch + nicotine lozenge)
Study: 30525116
Drug: LEV 1,000-3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV 1,000-3,000 mg/day
Study: 30525443
Drug: Free drug
Normalized name: sumatriptan 6 MG per 0.5 ML Needle-Free Drug Delivery System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free drug (irinotecan)
Study: 30526213
Drug: Cytisine, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytisine, a partial agonist for the α4β2 nicotinic acetylcholine receptor, administered in ascending single doses.
Study: 30526535
Drug: Initial high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial high-dose ganciclovir (6 mg)
Study: 30526535
Drug: Maintenance dose
Normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance dose of ganciclovir (not specified)
Study: 30527329
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg tablets
Study: 30527329
Drug: Raltegravir chewable
Normalized name: raltegravir Chewable Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir chewable tablets
Study: 30527329
Drug: Raltegravir oral
Normalized name: raltegravir Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir oral granules
Study: 30527329
Drug: Raltegravir (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir (all formulations)
Study: 30527774
Drug: Low-Molecular-Weight Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Molecular-Weight Heparin
Study: 30528561
Drug: tazobactam/ceftolozane 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: tazobactam/ceftolozane 1.5 g (tazobactam 0.5 g/ceftolozane 1 g) plus metronidazole 500 mg intravenously every 8 h for 60 min for 4-14 days
Study: 30528623
Drug: us-TnI <
Approvals — FDA: no, EMA: no, PMDA: no
Description: us-TnI < 1 ng/L directly on admission
Study: 30528623
Drug: us-TnI <
Approvals — FDA: no, EMA: no, PMDA: no
Description: us-TnI < 2 ng/L and 0/1h delta < 1 ng/L
Study: 30528623
Drug: us-TnI ≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: us-TnI ≥ 25 ng/L on admission or 0/1h delta ≥ 6 ng/L
Study: 30529029
Drug: Lopinavir-ritonavir super-boosting
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir-ritonavir super-boosting with additional ritonavir (one-to-one ratio) during rifampicin treatment
Study: 30529085
Drug: Levonorgestrel IUD
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel IUD (52-mg, 20 mcg/d initial release)
Study: 30530477
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (no pessary)
Study: 30530721
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral therapy with tenofovir disoproxil fumarate/emtricitabine
Study: 30530985
Drug: Oral d3-l-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral d3-l-carnitine
Study: 30530985
Drug: Chronic l-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic l-carnitine supplementation
Study: 30531015
Drug: Intrathecal injection
Normalized name: BACLOFEN 50 ug in 1 mL INTRATHECAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal injection of Wharton's jelly-derived mesenchymal stem cells (average dose of 0.42 × 10^6 cells)
Study: 30531565
Drug: Levonorgestrel 52-mg
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel 52-mg intrauterine system (IUS)
Study: 30534007
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg or 20 mg, bodyweight-adjusted, single-dose)
Study: 30534008
Drug: Rivaroxaban (tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (tablet and oral suspension)
Study: 30534187
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil omega-3 (3.17 g per day; eicosapentaenoic acid 2.15 g; docosahexaenoic acid 1.02 g)
Study: 30534374
Drug: Rasagiline 1
Normalized name: rasagiline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 1 mg once daily
Study: 30535053
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care models that integrate comorbidities, mainly via transdiagnostic self-management support, interprofessional collaboration, and digital approaches for treatment, monitoring, and communication.
Study: 30535190
Drug: Ceftaroline 600
Normalized name: ceftaroline 600 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftaroline 600 mg as a 1 h intravenous infusion
Study: 30536725
Drug: G-AgP
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-AgP
Study: 30537529
Drug: Sirolimus (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (loading dose of 1.8 mg/m)
Study: 30537545
Drug: 2000 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 μg vitamin D oral bolus
Study: 30537877
Drug: Interactions with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactions with biological and nonbiological network members regarding risk information and management strategies.
Study: 30537968
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide (CP) gel for 1 hour daily for 3 weeks
Study: 30537968
Drug: 10% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% carbamide peroxide (CP) gel
Study: 30538057
Drug: Aspirin/rivaroxaban co-therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin/rivaroxaban co-therapy
Study: 30538817
Drug: Anifrolumab treatment
Normalized name: anifrolumab
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anifrolumab treatment
Study: 30539492
Drug: Locoregional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional treatment (LRT) including radiotherapy, surgery, or both
Study: 30540645
Drug: ST-2 levels
Normalized name: STS
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ST-2 levels greater than 54 ng/ml
Study: 30540645
Drug: BNP levels
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP levels greater than 567 pg/ml
Study: 30541333
Drug: LifeCourse (LC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LifeCourse (LC) program delivered by community health workers (CHWs) with standardized monthly 1-hour home visits based on palliative care guidelines and motivational interviewing.
Study: 30541505
Drug: Point-of-care testing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point-of-care testing for procalcitonin (PCT) using 0.5 ml of whole blood; results available within 20 minutes.
Study: 30542286
Drug: Low-dose azacitidine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose azacitidine (AZA) in combination with PPARγ agonist pioglitazone (PGZ)
Study: 30542289
Drug: Daily undulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily undulating periodization (DUP) resistance training
Study: 30542377
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of everolimus, lapatinib, and capecitabine
Study: 30542622
Drug: Dalteparin sodium
Normalized name: Dalteparin Sodium
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin sodium (initial dose of 5000 IU, adjustable by 500 or 1000 IU increments)
Study: 30543050
Drug: Gastrin-releasing peptide
Normalized name: Gastrin-releasing peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrin-releasing peptide receptor antagonist
Study: 30543347
Drug: Alpelisib 400
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alpelisib 400 mg once daily plus fulvestrant 500 mg
Study: 30543347
Drug: Alpelisib 300
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpelisib 300 to 400 mg once daily plus fulvestrant
Study: 30543347
Drug: Alpelisib 300
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpelisib 300 mg once daily plus fulvestrant
Study: 30544060
Drug: Upfront DPYD-guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront DPYD-guided dose individualisation with initial dose reduction of 25% or 50% based on DPYD variants screening.
Study: 30544060
Drug: Upfront DPYD-guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront DPYD-guided dose individualisation.
Study: 30546962
Drug: Zolbetuximab in
Normalized name: zolbetuximab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolbetuximab in conjunction with chemotherapy
Study: 30548438
Drug: AVXS-101 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AVXS-101 gene replacement therapy
Study: 30551202
Drug: Carbonic anhydrase
Normalized name: Carbonic anhydrase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbonic anhydrase inhibitor (CAI) treatment
Study: 30551202
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (natural history)
Study: 30552056
Drug: Ledipasvir (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir (90 mg) and sofosbuvir (400 mg) in a single combination tablet once daily for 12 weeks
Study: 30552156
Drug: Vinflunine 280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinflunine 280 mg/m2
Study: 30552156
Drug: Vinflunine 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinflunine 320 mg/m2
Study: 30554141
Drug: GDF-15 levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDF-15 levels <564 pg/L
Study: 30555051
Drug: Coformulated elvitegravir
Normalized name: Elvitegravir
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Coformulated elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg once daily, taken after haemodialysis for up to 96 weeks.
Study: 30555048
Drug: Sofosbuvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (400 mg) and Velpatasvir (100 mg) tablet once daily for 12 weeks
Study: 30555280
Drug: Repetitive administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repetitive administration of intravenous levosimendan after discharge from an acute episode of worsening heart failure.
Study: 30555280
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy for advanced heart failure.
Study: 30555384
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy modules
Study: 30555714
Drug: Lumbar Spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar Spinal Manipulative Therapy (SMT)
Study: 30556332
Drug: Testosterone (T)/Nestorone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (T)/Nestorone (NES) combination gel applied by men (62 mg/8 mg)
Study: 30557521
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg every 2 weeks for 2 years or until confirmed disease progression or unacceptable toxicity
Study: 30557741
Drug: Wireless Motility
Normalized name: careless weed pollen extract
DrugBank: Amaranthus palmeri pollen (DB10459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wireless Motility Capsule (WMC)
Study: 30558613
Drug: Eating breakfast
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eating breakfast daily throughout childhood
Study: 30558613
Drug: Daily family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily family dinner
Study: 30558909
Drug: Asfotase alfa
Normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Asfotase alfa (1 mg/kg three times per week subcutaneously, adjusted to 3 mg/kg three times per week if required) for up to 7 years
Study: 30558987
Drug: Umbralisib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umbralisib (800 mg once daily) plus Ibrutinib (420 mg for CLL, 560 mg for MCL)
Study: 30559420
Drug: Intravitreal injections
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injections of an antisense oligonucleotide to restore correct splicing
Study: 30559424
Drug: AZD5991 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5991 in combination with bortezomib or venetoclax
Study: 30559603
Drug: PRO-SELF© Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO-SELF© Plus Pain Control Program (PCP), 6-week intervention, weekly psychoeducational sessions
Study: 30559966
Drug: Physical Exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical Exercise and Dietary Therapy (PED-t)
Study: 30562390
Drug: Preconception anemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preconception anemia (hemoglobin <12 g/dL)
Study: 30562587
Drug: CMVPepVax (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMVPepVax (two injections at days 28 and 56 post-HCT)
Study: 30563754
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDCT) and autologous stem-cell transplantation (ASCT)
Study: 30563875
Drug: Midostaurin added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin added to chemotherapy
Study: 30563875
Drug: Midostaurin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midostaurin as single-agent maintenance therapy
Study: 30564373
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy eligibility
Study: 30565371
Drug: COMBO stent
Normalized name: NexGard Combo
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMBO stent treatment
Study: 30567529
Drug: Maintenance MAGE-A3
Normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maintenance MAGE-A3 CI monotherapy
Study: 30569038
Drug: Novel nano-iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel nano-iron supplement
Study: 30569759
Drug: Fluocinolone intravitreal
Normalized name: Fluocinolone Acetonide Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocinolone intravitreal implant (ILUVIEN)
Study: 30570077
Drug: Instituto Butantan
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Instituto Butantan seasonal trivalent influenza vaccine (TIV)
Study: 30570358
Drug: Subcutaneous Echogenicity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Echogenicity Grade
Study: 30570358
Drug: Subcutaneous Echo-Free
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Echo-Free Space Grade
Study: 30570502
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for POP
Study: 30570649
Drug: Pembrolizumab, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab, 200 mg administered intravenously every 3 weeks until disease progression, unacceptable toxic effects, or study withdrawal, for up to 2 years.
Study: 30570649
Drug: Pembrolizumab treatment-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab treatment-related adverse events.
Study: 30570744
Drug: Mocetinostat (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mocetinostat (70 mg 3 times per week escalating to 90 mg TIW)
Study: 30570763
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) pertuzumab (600 mg maintenance dose)
Study: 30570763
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) pertuzumab (1200 mg loading dose)
Study: 30570763
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) pertuzumab and trastuzumab (fixed-dose combination)
Study: 30571194
Drug: Contemporary Cohort
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Contemporary Cohort (CC)
Study: 30571969
Drug: Caspase 1/11
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspase 1/11 invalidation or pharmacological inhibition by Ac-YVAD-CMK injection
Study: 30572891
Drug: Smartphone app-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone app-based medication reporting
Study: 30572920
Drug: Aedes aegypti
Normalized name: Aedes taeniorhynchus
DrugBank: Aedes taeniorhynchus (DB10691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aedes aegypti salivary gland homogenate antibody intensity determinations by ELISA assays
Study: 30572922
Drug: LCAR-B38M CAR
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCAR-B38M CAR T cell therapy
Study: 30573448
Drug: Tapering of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering of interventions (for responders)
Study: 30573492
Drug: Psychotropic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic medication treatment
Study: 30573492
Drug: Quality of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality of psychotropic medication treatment
Study: 30573564
Drug: Single-agent bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-agent bortezomib
Study: 30574672
Drug: Risankizumab 150
Normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 150 mg subcutaneously once every 4 weeks for 12 weeks
Study: 30576085
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide (TAF) 25 mg daily
Study: 30576221
Drug: Nasal High-Flow
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal High-Flow Therapy
Study: 30576970
Drug: Durvalumab 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 10 mg/kg intravenously every 2 weeks for up to 12 months
Study: 30577927
Drug: Psychotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy treatment for depression (PCIT-ED)
Study: 30577988
Drug: Buparlisib plus
Normalized name: Buparlisib
DrugBank: Buparlisib (DB11666)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib plus weekly paclitaxel
Study: 30577988
Drug: Systemic chemotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy, paclitaxel (70 mg/m2)
Study: 30578023
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg once daily, taken orally without food, until progression or intolerance.